IN2014CN03892A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN03892A IN2014CN03892A IN3892CHN2014A IN2014CN03892A IN 2014CN03892 A IN2014CN03892 A IN 2014CN03892A IN 3892CHN2014 A IN3892CHN2014 A IN 3892CHN2014A IN 2014CN03892 A IN2014CN03892 A IN 2014CN03892A
- Authority
- IN
- India
- Prior art keywords
- genetically modified
- animals
- making
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
Abstract
The invention provides genetically modified non human animals that express a humanized MHC II protein (humanized MHC II a and ß polypeptides) as well as embryos cells and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552584P | 2011-10-28 | 2011-10-28 | |
PCT/US2012/062029 WO2013063340A1 (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN03892A true IN2014CN03892A (en) | 2015-10-16 |
Family
ID=47430036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3892CHN2014 IN2014CN03892A (en) | 2011-10-28 | 2012-10-26 |
Country Status (25)
Country | Link |
---|---|
US (6) | US8847005B2 (en) |
EP (4) | EP3590332B1 (en) |
JP (2) | JP6285361B2 (en) |
KR (2) | KR102113108B1 (en) |
CN (3) | CN108707608A (en) |
AU (4) | AU2012327205B2 (en) |
BR (1) | BR112014009941B1 (en) |
CA (1) | CA2852962C (en) |
CY (2) | CY1119283T1 (en) |
DK (3) | DK3272214T3 (en) |
ES (3) | ES2640241T3 (en) |
HK (2) | HK1196999A1 (en) |
HR (3) | HRP20220616T1 (en) |
HU (2) | HUE048511T2 (en) |
IL (3) | IL231895B (en) |
IN (1) | IN2014CN03892A (en) |
LT (3) | LT3590332T (en) |
MX (1) | MX355726B (en) |
PL (3) | PL2770822T3 (en) |
PT (3) | PT3272214T (en) |
RS (3) | RS59997B1 (en) |
RU (1) | RU2660564C2 (en) |
SG (3) | SG10201909638UA (en) |
SI (3) | SI2770822T1 (en) |
WO (1) | WO2013063340A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054865A2 (en) | 2006-04-26 | 2008-05-08 | L-3 Communications Security And Detection Systems, Inc. | Multi-source surveillance systems |
HUE048511T2 (en) | 2011-10-28 | 2020-07-28 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
RS53683B1 (en) | 2011-10-28 | 2015-04-30 | Regeneron Pharmaceuticals Inc. | Humanized il-6 and il-6 receptor |
CN111484999A (en) | 2013-02-20 | 2020-08-04 | 瑞泽恩制药公司 | Humanized T cell co-receptor mice |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
EP2967015B9 (en) * | 2013-03-11 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
LT3434101T (en) | 2013-09-23 | 2023-09-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized signal-regulatory protein gene |
NZ718655A (en) * | 2013-10-15 | 2022-08-26 | Regeneron Pharma | Humanized il-15 animals |
MX2016013241A (en) | 2014-04-08 | 2017-05-03 | Regeneron Pharma | Non-human animals having humanized fc-gamma receptors. |
NO2785538T3 (en) | 2014-05-07 | 2018-08-04 | ||
ES2783424T3 (en) | 2014-06-19 | 2020-09-17 | Regeneron Pharma | Non-human animals that have a humanized programmed cell death gene 1 |
CN107072184A (en) | 2014-09-19 | 2017-08-18 | 瑞泽恩制药公司 | Chimeric antigen receptor |
RU2726446C2 (en) | 2014-11-24 | 2020-07-14 | Регенерон Фармасьютикалз, Инк. | Non-human animals expressing humanised complex cd3 |
PT3850946T (en) | 2014-12-05 | 2024-01-02 | Regeneron Pharma | Non-human animals having a humanized cluster of differentiation 47 gene |
CN113349159B (en) | 2015-04-06 | 2022-11-11 | 瑞泽恩制药公司 | Humanized T cell-mediated immune response in non-human animals |
CA3003786C (en) | 2015-11-20 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
ES2908669T3 (en) * | 2016-02-04 | 2022-05-03 | Regeneron Pharma | Non-human animals that have a genetically modified ANGPTL8 gene |
CN109068621B (en) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | Rodent with humanized TMPRSS gene |
HUE061619T2 (en) | 2016-06-03 | 2023-07-28 | Regeneron Pharma | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
AU2018375796A1 (en) | 2017-11-30 | 2020-04-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
CA3093995A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
US11576984B2 (en) | 2018-03-26 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using |
KR20210031868A (en) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animal model of DITRA disease and uses thereof |
CN114585744A (en) * | 2019-10-22 | 2022-06-03 | 纽约市哥伦比亚大学理事会 | Transgenic pig, its production method and use, and method for producing human immune system mouse |
IL293330A (en) | 2019-12-02 | 2022-07-01 | Regeneron Pharma | Peptide-mhc ii protein constructs and uses thereof |
KR20230164150A (en) | 2021-03-31 | 2023-12-01 | 리제너론 파아마슈티컬스, 인크. | Genetically modified mice containing humanized cellular immune system components with improved diversity of the TCRβ repertoire |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
US20240099279A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69033493D1 (en) | 1989-07-25 | 2004-08-12 | Cell Genesys Inc | HOMOLOGOUS RECOMBINATION FOR UNIVERSAL DONOR CELLS AND CHIMERIC MAMMAL CELLS |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
AU728794B2 (en) | 1996-03-05 | 2001-01-18 | Scripps Research Institute, The | Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
CA2302779C (en) | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
US6147275A (en) * | 1998-03-30 | 2000-11-14 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
US7067308B1 (en) * | 2000-03-28 | 2006-06-27 | Bioagri Corporation | Vector for genetically modifying non-human animals |
US20030124524A1 (en) | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050050580A1 (en) | 2000-12-13 | 2005-03-03 | Masashi Gotoh | Transgenic animal expressing hla-a24 and utilization thereof |
EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
FR2827302B1 (en) * | 2001-07-13 | 2003-10-10 | Genoway | TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF |
US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
DE10347710B4 (en) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
WO2005085438A1 (en) | 2004-03-09 | 2005-09-15 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
DK1802193T3 (en) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Method of producing a homozygous mouse for genetic modification |
EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
NO347649B1 (en) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use. |
WO2009114400A1 (en) | 2008-03-07 | 2009-09-17 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
PL3241435T3 (en) | 2009-07-08 | 2021-12-13 | Kymab Limited | Animal models and therapeutic molecules |
CN101695587B (en) * | 2009-10-21 | 2012-08-29 | 上海中山医疗科技发展公司 | Method for preparing endothelial progenitor cell capturing bracket for gene modification and regulation |
WO2012007951A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
HUE048511T2 (en) | 2011-10-28 | 2020-07-28 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
CN111484999A (en) | 2013-02-20 | 2020-08-04 | 瑞泽恩制药公司 | Humanized T cell co-receptor mice |
EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
EP2967015B9 (en) | 2013-03-11 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
CN113349159B (en) | 2015-04-06 | 2022-11-11 | 瑞泽恩制药公司 | Humanized T cell-mediated immune response in non-human animals |
-
2012
- 2012-10-26 HU HUE17171524A patent/HUE048511T2/en unknown
- 2012-10-26 PT PT171715246T patent/PT3272214T/en unknown
- 2012-10-26 EP EP19189533.3A patent/EP3590332B1/en active Active
- 2012-10-26 IN IN3892CHN2014 patent/IN2014CN03892A/en unknown
- 2012-10-26 SG SG10201909638U patent/SG10201909638UA/en unknown
- 2012-10-26 EP EP22152099.2A patent/EP4052572A1/en active Pending
- 2012-10-26 BR BR112014009941-3A patent/BR112014009941B1/en active IP Right Grant
- 2012-10-26 ES ES12806199.1T patent/ES2640241T3/en active Active
- 2012-10-26 SI SI201231056T patent/SI2770822T1/en unknown
- 2012-10-26 MX MX2014004896A patent/MX355726B/en active IP Right Grant
- 2012-10-26 DK DK17171524.6T patent/DK3272214T3/en active
- 2012-10-26 SG SG10201510056SA patent/SG10201510056SA/en unknown
- 2012-10-26 CN CN201810239690.4A patent/CN108707608A/en active Pending
- 2012-10-26 SI SI201231738T patent/SI3272214T1/en unknown
- 2012-10-26 DK DK12806199.1T patent/DK2770822T3/en active
- 2012-10-26 RU RU2014116577A patent/RU2660564C2/en active
- 2012-10-26 PL PL12806199T patent/PL2770822T3/en unknown
- 2012-10-26 LT LTEP19189533.3T patent/LT3590332T/en unknown
- 2012-10-26 LT LTEP12806199.1T patent/LT2770822T/en unknown
- 2012-10-26 ES ES19189533T patent/ES2914374T3/en active Active
- 2012-10-26 KR KR1020187034955A patent/KR102113108B1/en active IP Right Grant
- 2012-10-26 WO PCT/US2012/062029 patent/WO2013063340A1/en active Application Filing
- 2012-10-26 PT PT191895333T patent/PT3590332T/en unknown
- 2012-10-26 SI SI201231999T patent/SI3590332T1/en unknown
- 2012-10-26 KR KR1020147014315A patent/KR101926442B1/en active IP Right Grant
- 2012-10-26 PT PT128061991T patent/PT2770822T/en unknown
- 2012-10-26 AU AU2012327205A patent/AU2012327205B2/en active Active
- 2012-10-26 PL PL17171524T patent/PL3272214T3/en unknown
- 2012-10-26 DK DK19189533.3T patent/DK3590332T3/en active
- 2012-10-26 RS RS20200224A patent/RS59997B1/en unknown
- 2012-10-26 EP EP12806199.1A patent/EP2770822B9/en active Active
- 2012-10-26 JP JP2014539027A patent/JP6285361B2/en active Active
- 2012-10-26 PL PL19189533T patent/PL3590332T3/en unknown
- 2012-10-26 CN CN201280065075.7A patent/CN104039133B/en active Active
- 2012-10-26 CA CA2852962A patent/CA2852962C/en active Active
- 2012-10-26 HR HRP20220616TT patent/HRP20220616T1/en unknown
- 2012-10-26 HU HUE12806199A patent/HUE034374T2/en unknown
- 2012-10-26 ES ES17171524T patent/ES2774488T3/en active Active
- 2012-10-26 EP EP17171524.6A patent/EP3272214B1/en active Active
- 2012-10-26 CN CN201810239986.6A patent/CN108401986B/en active Active
- 2012-10-26 SG SG11201400938UA patent/SG11201400938UA/en unknown
- 2012-10-26 RS RS20170897A patent/RS56330B1/en unknown
- 2012-10-26 LT LTEP17171524.6T patent/LT3272214T/en unknown
- 2012-10-26 US US13/661,116 patent/US8847005B2/en active Active
- 2012-10-26 RS RS20220473A patent/RS63220B1/en unknown
-
2014
- 2014-04-03 IL IL231895A patent/IL231895B/en active IP Right Grant
- 2014-08-08 US US14/455,237 patent/US9585373B2/en active Active
- 2014-10-23 HK HK14110588.1A patent/HK1196999A1/en unknown
-
2016
- 2016-01-11 IL IL243565A patent/IL243565A/en active IP Right Grant
- 2016-04-13 AU AU2016202317A patent/AU2016202317B2/en active Active
-
2017
- 2017-01-24 US US15/413,785 patent/US10219493B2/en active Active
- 2017-08-17 JP JP2017157497A patent/JP6652529B2/en active Active
- 2017-09-04 HR HRP20171327TT patent/HRP20171327T1/en unknown
- 2017-09-05 CY CY20171100934T patent/CY1119283T1/en unknown
-
2018
- 2018-02-27 AU AU2018201402A patent/AU2018201402C1/en active Active
- 2018-06-21 IL IL260209A patent/IL260209B/en active IP Right Grant
- 2018-07-24 HK HK18109591.4A patent/HK1250131A1/en unknown
-
2019
- 2019-01-10 US US16/244,892 patent/US11219195B2/en active Active
- 2019-01-10 US US16/244,912 patent/US10986822B2/en active Active
-
2020
- 2020-02-24 HR HRP20200305TT patent/HRP20200305T1/en unknown
- 2020-02-26 CY CY20201100178T patent/CY1122700T1/en unknown
-
2021
- 2021-01-22 AU AU2021200438A patent/AU2021200438B2/en active Active
- 2021-03-17 US US17/204,526 patent/US20210195878A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN03892A (en) | ||
MY178723A (en) | Genetically modified major histocompatibility complex mice | |
CY1121223T1 (en) | Mice EXPRESSING A HUMANIZED MAJOR COMPLIANCE COMPLEX | |
AU2013312359A8 (en) | Genetically modified non-human animals and methods of use thereof | |
IN2014CN03890A (en) | ||
MX2017006802A (en) | Non-human animals expressing humanized cd3 complex. | |
EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
CL2016003096A1 (en) | Methods for harvesting mammalian cell cultures | |
MX2016003636A (en) | Non-human animals having a humanized signal-regulatory protein gene. | |
IN2014MN01879A (en) | ||
EA201592269A1 (en) | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS | |
GT201300306A (en) | ANTI-ANGPTL3 ANTIBODIES AND USES OF THE SAME | |
MX2016008076A (en) | Human mesothelin chimeric antigen receptors and uses thereof. | |
MX346500B (en) | Methods and compositions for neural disease immunotherapy. | |
WO2014130671A8 (en) | Mice expressing humanized t-cell co-receptors | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
MX2017008817A (en) | Compositions and methods for protein glycosylation. | |
EA201290567A1 (en) | PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION | |
JO3244B1 (en) | Human il-23 antigen binding proteins | |
MY160590A (en) | Cd127 binding proteins | |
MX2012012928A (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies. | |
IN2014DN11201A (en) | ||
MA37749A1 (en) | Vaccines against bluetongue and African horse sickness virus | |
DK201300530A (en) | Vaccine relating to Pancreas disease in fish | |
EP3496530A4 (en) | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |